Is there benefit of β-blocking agents in the treatment of patients with the Marfan syndrome?

https://doi.org/10.1016/j.ijcard.2006.01.025Get rights and content

First page preview

First page preview
Click to open first page preview

References (8)

There are more references available in the full text version of this article.

Cited by (32)

  • Marfan syndrome revisited: From genetics to the clinic

    2020, Revista Portuguesa de Cardiologia
  • Marfan syndrome: A cardiovascular perspective

    2018, Diagnosis and Management of Adult Congenital Heart Disease: Third Edition
  • Marfan Syndrome: A Cardiovascular Perspective

    2017, Diagnosis and Management of Adult Congenital Heart Disease
  • Aortopathy in pregnancy

    2014, Seminars in Perinatology
    Citation Excerpt :

    Atenolol is avoided due to the association with fetal growth restriction. Aortic root surveillance with serial echocardiograms every 6–8 weeks in pregnancy is suggested.23,24 If not completed prior to pregnancy, genetic counseling is recommended early in gestation.

  • Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome

    2013, International Journal of Cardiology
    Citation Excerpt :

    Patients with MFS suffer from an increased risk of cardiovascular manifestations like (asymmetric) aortic root dilatation, mitral valve prolapse, impaired biventricular function and aortic dissection, the latter being the main cause of premature death [3–6]. However, it is hard to predict which MFS patient is prone for aortic dissection, since dissections may occur unexpectedly in non-dilated aortas [7] and after prophylactic aortic root surgery [8]. Originally, it was thought that MFS was due to structural deficiency of fibrillin-1, leading to weakened microfibrils [9].

  • Factors influencing prognosis in patients with Marfan syndrome after aortic surgery

    2011, Journal of Cardiothoracic and Vascular Anesthesia
    Citation Excerpt :

    Gersony et al33 concluded that there is no evidence that β-blockers offer any substantial benefit. However, Engelfriet and Mulder35 pointed to the inherent limitations in Gersony et al's meta-analysis and concluded that it should not lead clinicians to stop prescribing β-blockers in patients with the MFS. The prevailing view had been that most manifestations of MFS seem to implicate dysregulation of tumor growth factor-β activity and signaling.

View all citing articles on Scopus

Refers to: Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta blocker therapy on clinical outcome in patients with Marfan's syndrome: A meta-analysis. This issue.

View full text